

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 7/44	A1	(11) International Publication Number: WO 95/04520 (43) International Publication Date: 16 February 1995 (16.02.95)
(21) International Application Number: PCT/US94/08944 (22) International Filing Date: 8 August 1994 (08.08.94) (30) Priority Data: 08/103,289 6 August 1993 (06.08.93) US (71)(72) Applicant and Inventor: EMBRO, William, J. [US/US]; 6320 S.W. 13th Street, Gainesville, FL 32608 (US). (74) Agents: KENTOFFIO, Joseph, S. et al.; McCormick, Paulding & Huber, CityPlace II, 185 Asylum Street, Hartford, CT 06103-4102 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: METHOD AND COMPOSITION FOR TREATING MUCO-EPIDERMAL AND EPIDERMAL PAIN, INFLAMMATION AND INFECTION (57) Abstract A topical pharmaceutical preparation for the treatment of epidermal and muco-epidermal tissue is provided. The composition includes a therapeutic amount of chlorhexidine and at least one non-steroidal anti-inflammatory agent. A method for treating epidermal and muco-epidermal pain, inflammation, infection and lesion by applying the topical preparation directly to the affected site is also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD AND COMPOSITION FOR TREATING MUCO-EPIDERMAL AND
EPIDERMAL PAIN, INFLAMMATION AND INFECTION
BACKGROUND OF THE INVENTION

The present invention relates generally to pharmaceutical preparations for the treatment of muco-epidermal and epidermal tissue. More particularly, the present invention relates to gels, creams, solutions and other topical preparations including a mixture of chlorhexidine and at least one non-steroidal anti-inflammatory agent. The invention further provides a method for the treatment of muco-epidermal and epidermal tissue using such preparations.

The antimicrobial effects of chlorhexidine are well-documented. Chlorhexidine gels, rinses and creams are routinely used to control bacterial infections on mucosal epidermal and epidermal tissue. For example, chlorhexidine gels and rinses are widely used in dentistry for the treatment of periodontal disease. Non-steroidal anti-inflammatory agents such as ibuprofen, ketoprofen and indomethacin have application in the treatment of, for example, inflammatory diseases such as arthritis, general muscle, skeletal and joint pain and menstrual cramps.

While these compounds have been widely used individually by physicians and dentists in the above-described manner for many years, the effectiveness of a combination of chlorhexidine and a non-steroidal anti-inflammatory agent has not been appreciated.

Accordingly, it is the object of the present invention to provide a pharmaceutical preparation including a combination of chlorhexidine and at least one anti-inflammatory agent which together show a synergistic effect in the treatment of muco-epidermal and epidermal inflammation and infection.

It is a further object of the invention to provide a method for treating muco-epidermal and epidermal tissue using such preparations.

SUMMARY OF THE INVENTION

The present invention meets the above-stated objects and others that will become readily apparent by providing topical pharmaceutical preparations which include chlorhexidine and at least one non-steroidal anti-inflammatory agent. These active ingredients are incorporated into a gel, cream, solution, rinse or other pharmaceutically acceptable carrier and are applied topically to sites of epidermal and muco-epidermal inflammation, infection or lesion.

The preparations which are the subject of the present invention include a non-toxic amount of chlorhexidine and preferably include, as the non-steroidal anti-inflammatory agent, indomethacin, ibuprofen, ketoprofen or other prostaglandin inhibitors.

As demonstrated below by the various examples provided, the combination of chlorhexidine and a non-steroidal anti-inflammatory agent unexpectedly show a synergistic effect in the treatment of a number of conditions including, periodontal disease, acne, post-radiation therapy, post-chemotherapy therapy, post-surgical therapy, burns and non-specific epidermal and muco-epidermal infections.

The present invention is also directed to a method for treating epidermal and muco-epidermal tissue employing the above-described topical preparations. The course of therapy with such preparations generally requires one to three applications per day or is applied on an as needed basis, depending on the severity of the condition. Treatment includes directly applying the topical preparations to the affected site.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the-topical pharmaceutical preparations of the present invention include chlorhexidine in a therapeutically effective amount. For most therapies, from about 0.1 wt.% to about 1.0 wt.%, preferably about 0.2 wt.% of chlorhexidine, has been found to be effective. The preparations further include a non-toxic amount of at least one non-steroidal anti-inflammatory agent, most preferably indocin, ibuprofen and/or ketoprofen, in an amount ranging from about 2 wt.% to about 5 wt.% of the total preparation.

The active ingredients are incorporated into a solution, cream, rinse, lotion, gel or other acceptable carrier. In some instances, depending upon the particular carrier, the active ingredients are first solubilized and then incorporated into the carrier. The addition of a suspending agent to the carrier such as, for example, acacia powder, xanthan gum, methylcellulose, hydroxymethylcellulose or hydroxypropylcellulose, has been found to be particularly useful when compounding the carrier. In this regard, hydroxymethylcellulose gel is the preferred carrier where treatment requires manual application of the preparation to affected epidermal or muco-epidermal tissue.

Example I

Ten patients exhibiting advanced periodontal disease were treated with a preparation of 0.2% chlorhexidine and 2% ketoprofen incorporated into a

hydroxymethylcellulose gel. The patients were each instructed to apply one of the preparations to the affected gums with a tooth brush twice a day for a week. All of these patients experienced relief from pain, infection and inflammation after the prescribed course of therapy.

Example II

Two surgical patients were instructed to apply the preparation described in Example I to post surgical sites twice a day for seven days. In both cases pain, inflammation and infection at the affected sites were relieved.

Example III

Three patients exhibiting acne sores were instructed to apply the preparation described in Example I to the affected sites twice a day for seven days. In all cases, treatment with the preparations provided a reduction in the pain and inflammation associated with the sores.

Example IV

One patient undergoing radiation therapy and two patients undergoing chemotherapy were each instructed to apply the preparation described in Example I twice daily for one week. All three patients received relief from pain and showed faster healing rates of intraoral tissues following treatment with the prescribed preparations.

While preferred embodiments have been shown and described, various modifications and substitutions may be made without departing from the spirit and scope of the invention. For example, those skilled in the art will recognize that related derivatives of the active ingredients, such as pharmaceutically acceptable salts of chlorhexidine, and other prostaglandin inhibitors, such as flurbiprofen and naproxen, are useful in practicing the present invention

I Claim:

1. A topical pharmaceutical preparation for the treatment of epidermal and muco-epidermal tissue comprising a therapeutic amount of chlorhexidine and a non-toxic amount of at least one non-steroidal anti-inflammatory agent.
2. The topical preparation of claim 1 wherein the non-steroidal anti-inflammatory agent is a prostaglandin inhibitor.
3. The topical preparation of claim 1 wherein the non-steroidal anti-inflammatory agent is a prostaglandin inhibitor selected from the group consisting of indocin, ibuprofen, ketoprofen, flurbiprofen, naproxen and mixtures thereof.
4. The topical preparation of claim 1 wherein chlorhexidine is present in an amount ranging from about 0.1 wt.% to about 1.0 wt.% of the total preparation.
5. The topical preparation of claim 1 wherein the non-steroidal anti-inflammatory agent is present in an amount ranging from about 2 wt.% to about 5 wt.% of the total preparation.
6. The topical preparation of claim 1 wherein the preparation further comprises a pharmaceutical carrier incorporating the chlorhexidine and the non-steroidal anti-inflammatory agent.
7. The topical preparation of claim 6 wherein the carrier is selected from the group consisting of a solution, cream, rinse, lotion and gel.
8. A topical pharmaceutical preparation for the treatment of epidermal and muco-epidermal tissue comprising a therapeutic amount of chlorhexidine and at least one non-steroidal anti-inflammatory agent selected from the group consisting of indocin, ibuprofen, ketoprofen and mixtures thereof incorporated into a pharmaceutical carrier.

9. The topical preparation of claim 8 wherein the chlorhexidine is present in an amount ranging from about 0.1 wt.% to about 1.0 wt.% and the non-steroidal anti-inflammatory agent is present in an amount ranging from about 2 to about 5 wt.%.

10. The topical pharmaceutical preparation of claim 9 wherein the carrier is a gel.

11. A method for the treatment of epidermal and muco-epidermal tissue, said method comprising the steps of:

providing a topical pharmaceutical preparation including a carrier incorporating a therapeutic amount of chlorhexidine and a non-toxic amount of at least one non-steroidal anti-inflammatory agent, and

applying the preparation directly to epidermal and muco-epidermal tissue having pain, inflammation, infection or lesion associated therewith.

12. The method of claim 11 further characterized in that the non-steroidal anti-inflammatory agent is a prostaglandin inhibitor selected from the group consisting of indocin, ibuprofen, ketoprofen, flurbiprofen, naproxen and mixtures thereof.

13. The method of claim 11 further characterized in that the chlorhexidine is present in an amount ranging from about 0.1 wt.% to about 1.0 wt.% and the non-steroidal anti-inflammatory agent is present in an amount ranging from about 2 to about 5 wt.%.

14. The method of claim 11 further characterized in that the carrier is selected from the group consisting of a solution, cream, rinse, lotion and gel.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/08944

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 7/44

US CL : 424/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/60

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
noneElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS, MEDLINE, CAS ONLINE, DERWENT**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,767,751 (Davis) 30 August 1988, see entire Document.	1-14
Y	US, A, 4,975,271 (Dunn et al) 04 December 1990, see entire Document.	1-14
Y	US, A, 4,789,667 (Makino et al) 06 December 1988, see entire Document.	1-14
Y	US, A, 4,814,176 (Makino et al) 21 March 1989, see entire Document.	1-14
Y	US, A, 5,102,666 (Acharya) 07 April 1992, see entire Document.	1-14
Y	US, A, 5,230,895 (Czarnecki et al.) 27 July 1993, see entire Document.	1-14

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

24 OCTOBER 1994

Date of mailing of the international search report

01 NOV 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SAMUEL BARTS

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/08944

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,740,365 (Yukimatsu et al) 26 April 1988, see entire Document.	1-14
Y	US, A, 4,906,670 (Higashi et al) 06 March 1990, see entire Document.	1-14